on Lir Life Sciences Corp. (CVE:SKNY)
LIR Life Sciences Partners with Oxygen Handel for Regulatory Roadmap
LIR Life Sciences Corp. has entered a development services agreement with Oxygen Handel GmbH. The focus is on creating a regulatory and development roadmap for its transdermal obesity pipeline. This agreement will guide LIR's transdermal GLP-1 and GLP/GIP-based therapeutics through regulatory pathways, including potential 505(b)(2) pathways. The roadmap will encompass study mapping, risk analysis, and budget forecasting.
The collaboration marks a significant milestone for LIR as it plans the systematic advancement of its transdermal delivery platform. The initial phase includes regulatory pathway analysis and gap assessment for formulation and nonclinical needs. The aim is to support future commercialization efforts.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lir Life Sciences Corp. news